Get the Stockscreener App
2.21
1.84%
0.04
Pre-market:
2.16
-0.05
-2.26%
Processa Pharmaceuticals Inc stock is traded at $2.21, with a volume of 29,705.
It is up +1.84% in the last 24 hours and down -25.34% over the past month.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
See More
Previous Close:
$2.17
Open:
$2.27
24h Volume:
29,705
Relative Volume:
0.46
Market Cap:
$6.08M
Revenue:
-
Net Income/Loss:
$-14.11M
P/E Ratio:
-0.2062
EPS:
-10.7181
Net Cash Flow:
$-13.60M
1W Performance:
-8.68%
1M Performance:
-25.34%
6M Performance:
-37.53%
1Y Performance:
-65.80%
1-Day Range:
$2.19
$2.32
1-Week Range:
$1.91
$2.595
52-Week Range:
$1.76
$19.63
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443-776-3133
Address
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
2.21 | 6.08M | 0 | -14.11M | -13.60M | -10.72 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Initiated | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
PCSA Q4 2025 Earnings: EPS Misses Estimates by 67.97% as Pre-Revenue Biotech Faces HeadwindsWeak Earnings Momentum - newsline.com
Processa Pharmaceuticals, Inc. - MLQ.ai
PCSA Stock Chart | PROCESSA PHARMACEUTICALS INC (NASDAQ:PCSA) - ChartMill
PCSA Stock Price, Quote & Chart | PROCESSA PHARMACEUTICALS INC (NASDAQ:PCSA) - ChartMill
Processa Pharmaceuticals CAO Wendy Guy buys $4,700 in stock By Investing.com - Investing.com India
Processa Pharmaceuticals CAO Wendy Guy buys $4,700 in stock - Investing.com
Insider Buying: Russell Skibsted Acquires Additional Shares of P - GuruFocus
Processa Pharmaceuticals’ pres. David Young buys $4,590 in stock By Investing.com - Investing.com India
Processa Pharmaceuticals chief business and strategy officer buys $4,065 in stock - Investing.com Nigeria
Processa Pharmaceuticals’ pres. David Young buys $4,590 in stock - Investing.com
Processa Pharmaceuticals (PCSA) R&D chief buys 1,786 shares at $2.57 - Stock Titan
Processa Pharmaceuticals (PCSA) CFO adds 2,292 shares in open-market buy - Stock Titan
Processa (NASDAQ: PCSA) CEO adds 2,129 shares in open-market buy - Stock Titan
Processa (NASDAQ: PCSA) officer adds to stake with share purchase - Stock Titan
Processa (PCSA) CAO Wendy Guy adds 1,829 shares in open-market buy - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Guy Wendy - Moomoo
Processa Pharmaceuticals (PCSA) Edges Lower as Biotech Volatility PersistsThe Legal Advocate - The Legal Advocate
Processa Pharmaceuticals (PCSA) Surges 5.75% as Shares Test Key Resistance LevelVolume Spike Alerts - The Legal Advocate
PCSA Q4 2025 Earnings: EPS Misses Estimates Amid Pipeline DevelopmentEarnings Decline Risk - The Legal Advocate
Processa Pharmaceuticals Inc. (PCSA) Q4 2025 Earnings: EPS Misses Estimates as Biotech Focuses on Clinical PipelineConsensus Miss Rate - newsline.com
Processa Pharmaceuticals Inc. (PCSA) Q4 2025 Earnings: Wider-Than-Expected Loss as Clinical Pipeline ProgressesGuidance Downgrade Alert - The Legal Advocate
Processa Pharmaceuticals CAO Wendy Guy buys $4,701 in stock By Investing.com - Investing.com India
Processa Pharmaceuticals CEO George Ng buys $5,473 in stock - Investing.com India
Processa Pharmaceuticals president David Young buys $4,588 in shares - Investing.com India
Processa Pharmaceuticals CEO George Ng buys $5,473 in stock By Investing.com - Investing.com South Africa
Sian Bigora, Processa CDO, buys $5,341 in stock - Investing.com UK
Processa Pharmaceuticals president David Young buys $4,588 in shares By Investing.com - Investing.com Australia
Processa Pharmaceuticals CAO Wendy Guy buys $4,701 in stock - Investing.com
Processa (NASDAQ: PCSA) strategy chief buys 1,369 shares in open market - Stock Titan
Processa (PCSA) CEO adds 1,843 shares and corrects prior Form 4 - Stock Titan
Processa (PCSA) R&D head buys 1,545 shares at $2.97 in open market - Stock Titan
Processa Pharmaceuticals (NASDAQ: PCSA) CAO purchases 1,583 shares and corrects prior Form 4 - Stock Titan
Processa Pharmaceuticals (PCSA) CFO adds 1,984 shares in Form 4 buy - Stock Titan
Processa (NASDAQ: PCSA) CEO George Ng buys 1,843 shares in open market - Stock Titan
Processa Pharmaceuticals (PCSA) CDO buys 1,971 shares in open-market trade - Stock Titan
What Processa Pharmaceuticals PCSA is doing that separates it from the herd Modest Gains 20260507Viral Momentum Stocks - Newser
Processa Pharmaceuticals (PCSA) holder CVI reports 200,000-share stake, 7.0% - Stock Titan
TradingKey - TradingKey
The valuation case for Processa Pharmaceuticals (PCSA) that is hard to ignore (+4.36%) 2026-05-08Gamma Squeeze - The Legal Advocate
Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Processa Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Ng George K - Moomoo
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Lin Patrick - Moomoo
2025 Executive Compensation, Ownership, and Governance Overview for Heatwurx, Inc. (Now Based in Vero Beach, FL) - minichart.com.sg
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SKIBSTED RUSSELL - Moomoo
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Processa Pharmaceuticals Inc Stock (PCSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SKIBSTED RUSSELL | Chief Financial Officer |
May 29 '26 |
Buy |
2.57 |
2,292 |
5,890 |
10,758 |
| Ng George K | Chief Executive Officer |
May 29 '26 |
Buy |
2.57 |
2,129 |
5,472 |
9,970 |
| Lin Patrick | Chief Business - Strategy Off |
May 29 '26 |
Buy |
2.57 |
1,582 |
4,066 |
9,176 |
| Guy Wendy | Chief Administrative Officer |
May 29 '26 |
Buy |
2.57 |
1,829 |
4,701 |
9,840 |
| Ng George K | Chief Executive Officer |
May 15 '26 |
Buy |
2.97 |
1,843 |
5,474 |
7,841 |
| Young David | Pres. Research & Development |
May 15 '26 |
Buy |
2.97 |
1,545 |
4,589 |
15,345 |
| Lin Patrick | Chief Business - Strategy Off |
May 15 '26 |
Buy |
2.97 |
1,369 |
4,066 |
7,594 |
| Guy Wendy | Chief Administrative Officer |
May 15 '26 |
Buy |
2.97 |
1,583 |
4,702 |
8,011 |
| SKIBSTED RUSSELL | Chief Financial Officer |
May 15 '26 |
Buy |
2.97 |
1,984 |
5,892 |
8,466 |
| Young David | Pres. Research & Development |
Apr 30 '26 |
Buy |
2.69 |
1,706 |
4,589 |
13,813 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):